BNVI - Bionovo, Inc.

[Hot Christian Stocks]

About Bionovo, Inc.
Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources, which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes it has discovered new classes of drug candidates within its rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and its stock is traded on the OTC Link Platform under the symbol "BNVI.PK." For more information about Bionovo and its programs, visit www.bionovo.com

Contact

Bionovo, Inc.
5858 Horton Street, Suite 400
Emeryville, CA 94608

510-601-2000
510-601-5050 (FAX)

www.otcmarkets.com/stock/BNVI/quote

Bionovo Management

Isaac Cohen, O.M.D., L.Ac.
Dr. Cohen is a co-founder of Bionovo, Inc., and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri is a co-founder of Bionovo, Inc., and has served as its Chief Regulatory Officer, Chief Medical Officer, Secretary and Treasurer and as a director since February 2002. She became Vice President, Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer of Bionovo, Inc. in April 2005, and a Director effective May 2005. She became President of Bionovo, Inc. in addition to continuing her functions as the Company’s Chief Medical Officer, Secretary, Treasurer and Director in May 2007. Dr. Tagliaferri conducted translational research at the University of California, San Francisco from 1996-2002.

David Boyle
Mr. Boyle is Senior Vice President and Chief Financial Officer at Bionovo, Inc. and has served in this role since early 2012. He was previously Senior Vice President and Chief Financial Officer of AVI BioPharma, Inc., a Washington-based company developing RNA-based therapeutics. Prior to AVI, he was Vice President, Finance and Chief Financial Officer of XOMA, Ltd., a California-based leader in the discovery and development of therapeutic antibodies. In addition to his past positions as Vice President of Finance at Polycom and Director of Business Development at Intel, Mr. Boyle has held senior positions in biotechnology and specialty pharmaceutical companies. He was previously at Salix Pharmaceuticals, Ltd. in the U.S. and at Ares Serono Group both in the U.S. and Switzerland..

Bionovo Board of Directors

Isaac Cohen, O.M.D., L.Ac.
Dr. Cohen is a co-founder of Bionovo Pharmaceuticals, Inc. (“Bionovo Pharmaceuticals”), and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri is a co-founder of Bionovo Pharmaceuticals, and has served as its Chief Regulatory Officer, Chief Medical Officer, Secretary and Treasurer and as a director since February 2002. She became Vice President, Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer of Bionovo, Inc. in April 2005, and a Director effective May 2005. She became President of Bionovo, Inc. in addition to continuing her functions as the Company’s Chief Medical Officer, Secretary, Treasurer and Director in May 2007. Dr. Tagliaferri conducted translational research at the University of California, San Francisco from 1996-2002.

Louis Drapeau
Mr. Drapeau has been a Director since March 14, 2008 and serves as our Lead Independent Director and the chair of our Audit Committee. Mr. Drapeauis has been Chief Financial Officer of InSite Vision since 2007 and served as the Company's Chief Executive Officer from November 2008 to December 2010. Prior to InSite Vision, he served as Chief Financial Officer, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company headquartered in San Carlos, California from January 2006 to August 2007. Prior to Nektar, Mr. Drapeau served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior Vice President and Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc, a pharmaceutical company. Previously, Mr. Drapeau spent more than 30 years at Arthur Andersen. Mr. Drapeau also serves on the boards of Intermune, Inc., a pharmaceutical company and Bio-Rad Laboratories, a life science and clinical diagnosis company. Mr. Drapeau is an independent and unaffiliated director, and serves as the chair of our Audit Committee.

George C. Butler, Ph.D.
Dr. Butler has been a Director since March 11, 2008. Currently, Dr. Butler serves as the Chairman and President of SingEval (Singapore) Pte. Ltd., a drug development company based in Singapore and the US. Dr. Butler was formerly the vice president, Customer Relationships, Global Development of AstraZeneca, plc, a global pharmaceutical company. Prior to this, he was Vice President, head of regulatory affairs. Prior to his time at AstraZeneca, Dr. Butler was vice president and head of regulatory affairs with Novartis AG. Dr. Butler has over 30 years of healthcare research and business experience, primarily in a development environment in multiple biopharmaceutical companies and has also been active for many years in advancing Asian-Western development/regulatory single programs. Dr. Butler is an independent and unaffiliated director, and serves on our Compensation and Nominations Committee.

Robert Farrell, J.D.
Mr. Farrell held the positions of Executive Vice President and CFO of Titan Pharmaceuticals, Inc. and was appointed President and CEO of Titan in December 2008, a position that he held through 2009. Prior to Titan Pharmaceuticals, from 1991-1996, Mr. Farrell served as Corporate Group Vice President and CFO of Fresenius USA, a pharmaceutical manufacturing and medical device company focused on the treatment of end-stage renal disease. Mr. Farrell holds an undergraduate degree from the University of Notre Dame and received his J.D.degree from the University of California.


bionovo.com/pipeline/overview

Menerba® for the Treatment of Vasomotor Symptoms (Hot Flashes) Associated with Menopause

Seala® for Postmenopausal Vaginal Atrophy and Dryness

Bezielle® for the Treatment of Advanced Breast Cancer

Bezielle® for the Treatment of Pancreatic Cancer

bionovo.com/static/doc/presentations/Company_Overview_Presentation.pdf

bionovo.com/static/doc/presentations/Bionovo_Fact_Sheet.pdf

[Hot Christian Stocks]

BNVI President & CMO Receives Women of the Year Award
Dr. MaryTagliaferri to accept award as one of the distinguished women in California's 14th Assembly District

BNVI.PK 0.09 +0.00

EMERYVILLE, Calif., March 8, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that its President and Chief Medical Officer will be awarded as one of California's 14th Assembly District Women of the Year at an awards ceremony taking place on March 8, 2012. Dr. Tagliaferri is being honored for her notable accomplishments in empowering women within the biotechnology and medical fields as well as serving as a role model and leader to women within the district.
(Logo: photos.prnewswire.com/prnh/20111110/SF04662LOGO)
"It is such an honor to be recognized by Assemblymember Skinner as well as those who have nominated me for this award," said Dr. Tagliaferri. "My close colleagues and I have devoted our careers and research efforts to discovering safe and effective drugs derived from botanical sources for the treatment of breast cancer and menopause. At Bionovo, we are aiming to provide the 40 million women transitioning through menopause with a safer alternative to hormone therapy with the advancement of Menerba, our late stage development drug for the treatment of menopausal symptoms."
Dr. Tagliaferri is both an M.D., trained at the University of California, San Francisco and a licensed traditional Chinese medicine practitioner with a Master's degree in Oriental Medicine. As Co-founder, President and Chief Medical Officer of Bionovo, she is not only dedicated to bringing forward FDA approved botanical therapies, but she is also passionately dedicated to education and public awareness around women's health issues which are reflected in the two books she has authored; Breast Cancer: Beyond Convention (Atria Press: 2002) and The New Menopause Book (Avery Press: 2006).
Dr. Tagliaferri's collaborative research efforts with Dr. Isaac Cohen have led to significant medical discoveries that botanical drugs derived from traditional Chinese medicine not only appear to have statistically significant efficacy, but have mechanisms of action that yield safer therapies for symptoms associated with menopause. These groundbreaking advancements have the potential to revolutionize the field of women's health and provide a new drug development pathway for novel therapies derived from natural products.
"Dr. Tagliaferri's accomplishments are particularly important to the empowerment of women because the discoveries that she is leading will help forge the path for new treatments for menopause and breast cancer," said Assemblymember Nancy Skinner (D-14), host of the 2012 Women of the Year Empowerment Dinner. "It is wonderful to have the opportunity to recognize women, such as Dr. Tagliaferri, who dedicate their lives to serving women in our community and beyond."
About Bionovo, Inc.
Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources, which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes it has discovered new classes of drug candidates within its rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and its stock is traded on the OTC Link Platform under the symbol "BNVI.PK." For more information about Bionovo and its programs, visit www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.